戻る Agenda
Session 1: The Basics: Why We Do What We Do
Session Chair(s)
William Gregory, PHD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
- This session provides longitudinal context for the evolving safety profile in a clinical development program and why continuous safety monitoring and evaluation are important. Three case studies underscore the importance of impeccable attention to drug safety during all phases of clinical development.